CRISPR Therapeutics AG (NASDAQ:CRSP) Given Average Rating of “Hold” by Brokerages

Shares of CRISPR Therapeutics AG (NASDAQ:CRSP) have been given an average rating of “Hold” by the eighteen brokerages that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, eight have issued a hold recommendation and nine have assigned a buy recommendation to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $77.93.

Several research firms have commented on CRSP. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $53.00 price target on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. Needham & Company LLC restated a “buy” rating and issued a $84.00 target price on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. JMP Securities reiterated a “market outperform” rating and set a $86.00 price target on shares of CRISPR Therapeutics in a research report on Friday, December 20th. Barclays lowered their price objective on CRISPR Therapeutics from $59.00 to $55.00 and set an “equal weight” rating on the stock in a research report on Wednesday, November 6th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $94.00 target price on shares of CRISPR Therapeutics in a report on Tuesday, December 10th.

CRISPR Therapeutics Stock Down 2.6 %

Shares of NASDAQ:CRSP opened at $40.02 on Friday. CRISPR Therapeutics has a 52-week low of $39.41 and a 52-week high of $91.10. The stock has a market cap of $3.42 billion, a price-to-earnings ratio of -14.14 and a beta of 1.62. The business has a 50-day moving average price of $47.85 and a 200-day moving average price of $50.27.

CRISPR Therapeutics (NASDAQ:CRSP) last posted its quarterly earnings results on Tuesday, November 5th. The company reported ($1.01) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.42) by $0.41. The company had revenue of $0.60 million during the quarter, compared to analyst estimates of $6.65 million. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. During the same period last year, the firm posted ($1.41) EPS. As a group, equities analysts anticipate that CRISPR Therapeutics will post -5.13 EPS for the current fiscal year.

Insider Buying and Selling at CRISPR Therapeutics

In other news, General Counsel James R. Kasinger sold 1,089 shares of the company’s stock in a transaction that occurred on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the sale, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This represents a 1.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Samarth Kulkarni sold 4,293 shares of the business’s stock in a transaction on Monday, October 14th. The stock was sold at an average price of $46.28, for a total value of $198,680.04. Following the transaction, the chief executive officer now directly owns 226,540 shares in the company, valued at $10,484,271.20. This trade represents a 1.86 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 50,382 shares of company stock worth $2,744,179. Corporate insiders own 4.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Capital Advisors Inc. OK increased its position in CRISPR Therapeutics by 8.1% during the third quarter. Capital Advisors Inc. OK now owns 300,589 shares of the company’s stock worth $14,122,000 after purchasing an additional 22,583 shares during the last quarter. Granite Bay Wealth Management LLC purchased a new stake in shares of CRISPR Therapeutics in the 2nd quarter valued at approximately $2,375,000. Geode Capital Management LLC increased its holdings in shares of CRISPR Therapeutics by 3.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,008,214 shares of the company’s stock worth $47,383,000 after buying an additional 35,196 shares during the last quarter. State Street Corp raised its position in shares of CRISPR Therapeutics by 25.0% during the 3rd quarter. State Street Corp now owns 2,992,988 shares of the company’s stock valued at $140,611,000 after buying an additional 599,304 shares during the period. Finally, International Assets Investment Management LLC acquired a new position in CRISPR Therapeutics in the third quarter valued at approximately $1,825,000. Hedge funds and other institutional investors own 69.20% of the company’s stock.

About CRISPR Therapeutics

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.